# US 2003/0069174 A1 · Use of human alpha1-acid glycoprotein for producing a pharmaceutical preparation

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2003/0069174 A1
- Document ID: US20030069174A1
- Status: Published application
- Kind: A1
- Application number: 10/298,942
- Filed: 2002-11-19
- Published: 2003-04-10
- Earliest claimed: 1997-03-10
- Inventors: Ludwig Pichler; Eva-Maria Muchitsch; Anton Philapitsch; Hans-Peter Schwarz; Yendra Linnau; Wolfgang Teschner
- Web page: https://patentgrep.com/patent/US20030069174A1

## CPC

- A61K 38/1709: {from mammals}
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The invention relates to the use of human α1-acid glycoprotein (AGP) for producing a pharmaceutical preparation for treating non-inflammatory disturbances of circulation or microcirculation, respectively.

## Claims

### Claim 1

The use of human α1-acid glycoprotein for producing a pharmaceutical preparation for treating non-inflammatory disturbances of circulation or microcirculation, respectively.

### Claim 2 (depends on 1)

The use according to claim 1, characterized in that the preparation is suitable for the treatment of hemorrhagic shock and/or hypovolemic shock.

### Claim 3 (depends on 2)

The use according to claim 2, characterized in that the preparation is suitable for stabilizing the intravasal volume, in particular in case of acute hemorrhages, excessive loss of liquid or vasodilation, respectively.

### Claim 4 (depends on 1)

The use according to claim 1, characterized in that the preparation is suitable for preventing reperfusion damages occurring in connection with a reduced perfusion.

### Claim 5 (depends on 4)

The use according to claim 4, characterized in that the preparation is suitable for preventing reperfusion damages as a consequence of a stroke, in particular for reducing cerebral oedema.

### Claim 6 (depends on 1)

The use according to claim 1, characterized in that the preparation is suitable for treating microcirculatory disturbances in organs, in particular in the kidney.

### Claim 7 (depends on 6)

The use according to claim 6, characterized in that the preparation is suitable for treating proteinuria.

### Claim 8 (depends on 6)

The use according to claim 6, characterized in that the preparation is suitable for preventing or treating, respectively, oedemas.

### Claim 9 (depends on 1, 2, 3, 4, 5, 6, 7, 8)

The use according to any one of claims 1 to 8, characterized in that the pharmaceutical preparation is produced as a storage-stable infusion solution.

### Claim 10 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9)

The use according to any one of claims 1 to 9, characterized in that the pharmaceutical preparation is produced as a lyophilisate.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The use according to any one of claims 1 to 10, characterized in that the pharmaceutical preparation is used in a dose ranging from 70 mg/kg to 5 g/kg, in particular ranging from 100 to 700 mg/kg.

### Claim 12 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11)

The use according to any one of claims 1 to 11, characterized in that the pharmaceutical preparation comprises at least 50% of α1-acid glycoprotein, in particular more than 70%, preferably more than 90%, based on the total protein.

### Claim 13 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12)

The use according to any one of claims 1 to 12, characterized in that the pharmaceutical preparation further comprises albumin.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13)

The use according to any one of claims 1 to 13, characterized in that the pharmaceutical preparation comprises a stabilizer, in particular sodium caprylate.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14)

The use according to any one of claims 1 to 14, characterized in that the pharmaceutical preparation is treated for virus inactivation or virus depletion, respectively, in particular by at least one physical treatment, such as heat treatment and/or filtration.

### Claim 16 (depends on 2)

The use according to claim 2, characterized in that the treatment comprises an administration of vasoactive substances, in particular catechol amines.

### Claim 17 (depends on 16)

The use according to claim 16, characterized in that the vasoactive substances are administered together or in parallel.

### Claim 18

Infusion preparation for treating shock conditions, comprising α1-acid glycoprotein and a vasoactive substance as its active components.

### Claim 19

A kit for treating shock conditions, comprising
a) α1-acid glycoprotein in a pharmaceutical preparation, and
b) a vasoactive substance.
